Deferasirox
- Generic Name
- Deferasirox
- Brand Names
- Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15N3O4
- CAS Number
- 201530-41-8
- Unique Ingredient Identifier
- V8G4MOF2V9
- Background
Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
- Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
- Associated Conditions
- Chronic Iron Overload
- Associated Therapies
- -
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT00379483
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 184
- Registration Number
- NCT00303329
- Locations
- 🇺🇸
Childres's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Stanford Hospital, Stanford, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
- Conditions
- Diamond Blackfan AnemiaThalassemiaSickle Cell DiseaseMyelofibrosis
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1683
- Registration Number
- NCT00235391
- Locations
- 🇮🇹
Azienda Ospedali Vittorio Emanuele, Ferrarotto e San Bambino, Catania, Italy
🇮🇹PresidioOspedaliero S. Luigi Curro, Catania, Italy
🇺🇸PCTI, Columbus, Ohio, United States
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 252
- Registration Number
- NCT00171171
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
🇱🇧Ali Taher, Beirut, Lebanon
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1784
- Registration Number
- NCT00171821
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
- Conditions
- Beta-thalassemia MajorHemosiderosisIron OverloadRare Anemia
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 233
- Registration Number
- NCT00171301
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
- Conditions
- Transfusional Iron Overload in β-thalassemia
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 506
- Registration Number
- NCT00171210
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00117507
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT00110266
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, United States
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
- Conditions
- Beta-thalassemiaMyelodysplastic SyndromesFanconi SyndromeAnemia, AplasticAnemia, Diamond-Blackfan
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT00061763
- Locations
- 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.